Bryan Laffitte
Overview
Explore the profile of Bryan Laffitte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
610
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Jin Q, Ding Q, Hao X, Mo T, Yan S, et al.
ChemMedChem
. 2020 Jul;
15(16):1562-1570.
PMID: 32613743
Loss of β-cell mass and function can lead to insufficient insulin levels and ultimately to hyperglycemia and diabetes mellitus. The mainstream treatment approach involves regulation of insulin levels; however, approaches...
2.
Hohmeier H, Zhang L, Taylor B, Stephens S, Lu D, McNamara P, et al.
PLoS One
. 2020 Mar;
15(3):e0224344.
PMID: 32176701
A key event in the development of both major forms of diabetes is the loss of functional pancreatic islet β-cell mass. Strategies aimed at enhancing β-cell regeneration have long been...
3.
Liu Y, Jin Q, Zou Y, Ding Q, Yan S, Wang Z, et al.
J Med Chem
. 2020 Feb;
63(6):2958-2973.
PMID: 32077280
Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting β-cell proliferation could be one approach...
4.
Chianelli D, Rucker P, Roland J, Tully D, Nelson J, Liu X, et al.
J Med Chem
. 2020 Jan;
63(8):3868-3880.
PMID: 31940200
Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for the treatment of nonalcoholic steatohepatitis (NASH) patients, as they exert positive effects on multiple aspects of the disease....
5.
Badman M, Chen J, Desai S, Vaidya S, Neelakantham S, Zhang J, et al.
Clin Pharmacol Drug Dev
. 2019 Dec;
9(3):395-410.
PMID: 31823525
Tropifexor (LJN452) is a potent, orally available, non-bile acid farnesoid X receptor agonist under clinical development for chronic liver diseases. Here, we present results from a first-in-human study of tropifexor...
6.
Hernandez E, Zheng L, Kim Y, Fang B, Liu B, Valdez R, et al.
Hepatol Commun
. 2019 Aug;
3(8):1085-1097.
PMID: 31388629
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid-derived FXR agonist obeticholic acid (OCA) has shown...
7.
Jacintho J, Baccei C, Bravo Y, Broadhead A, Chen A, Correa L, et al.
Bioorg Med Chem Lett
. 2018 Dec;
29(3):503-508.
PMID: 30594433
We previously published on the design and synthesis of novel, potent and selective PPARα antagonists suitable for either i.p. or oral in vivo administration for the potential treatment of cancer....
8.
Xu J, Mathur J, Vessieres E, Hammack S, Nonomura K, Favre J, et al.
Cell
. 2018 Apr;
173(3):762-775.e16.
PMID: 29677517
Mechanotransduction plays a crucial role in vascular biology. One example of this is the local regulation of vascular resistance via flow-mediated dilation (FMD). Impairment of this process is a hallmark...
9.
Tully D, Rucker P, Chianelli D, Williams J, Vidal A, Alper P, et al.
J Med Chem
. 2017 Nov;
60(24):9960-9973.
PMID: 29148806
The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases...
10.
Hao X, Jin Q, Va P, Li C, Shen W, Laffitte B, et al.
ChemMedChem
. 2016 Apr;
11(11):1129-32.
PMID: 27095073
Our research groups recently described a series of small-molecule inducers of β-cell proliferation that could be used to increase β-cell mass. To mitigate the risk of nonspecific proliferation of other...